Purinone derivatives as HM74A agonists

Details Purinone derivatives as HM74A agonists Purinone derivatives as HM74A agonists

2011-01-04

2011-01-04

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

07863285

ABSTRACT:
The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.

REFERENCES:
patent: 4404380 (1983-09-01), Temple, Jr.
patent: 6902902 (2005-06-01), Unett et al.
patent: 7462624 (2008-12-01), Xue et al.
patent: 7511050 (2009-03-01), Zheng et al.
patent: 2004/0254224 (2004-12-01), Foord et al.
patent: 2005/0004178 (2005-01-01), Unett et al.
patent: 2006/0078916 (2006-04-01), Aguilar et al.
patent: 2006/0160132 (2006-07-01), Golz et al.
patent: 2009/0088446 (2009-04-01), Xue et al.
patent: 417790 (1991-03-01), None
patent: 1 092 435 (1999-07-01), None
patent: 1092435 (2001-04-01), None
patent: 1251130 (2002-10-01), None
patent: WO 90/01031 (1990-02-01), None
patent: WO 98/56820 (1998-12-01), None
patent: WO 00/01388 (2000-01-01), None
patent: WO 01/47931 (2001-07-01), None
patent: WO 02/00196 (2002-01-01), None
patent: WO 02/44182 (2002-06-01), None
patent: WO 02/084298 (2002-10-01), None
patent: WO 03/022284 (2003-03-01), None
patent: WO 2004/071378 (2004-08-01), None
patent: WO 2005/077950 (2005-08-01), None
patent: WO 2006/021892 (2006-03-01), None
patent: WO 2006/045564 (2006-05-01), None
patent: WO 2006/045565 (2006-05-01), None
patent: WO 2007/017261 (2007-02-01), None
patent: WO 2007/017262 (2007-02-01), None
patent: WO 2007/017265 (2007-02-01), None
Defronzo, et al., Dysfunctional Fat Cells, Lipotoxicity and Type 2 Diabetes, Int. J. Clin. Prac., 58: 9-21 (2004).
Office Action dated Jun. 10, 2010 received in copending U.S. Appl. No. 12/237,794.
Office Action dated May 26, 2010 received in copending U.S. Appl. No. 12/263,990.
U.S. Appl. No. 12/237,794, filed Sep. 25, 2008, Xue et al.
U.S. Appl. No. 12/263,990, filed Nov. 3, 2008, Xue et al.
Altschul, et al., “Influence of nicotinic acid on serum cholesterol in man”,Arch. Biochem, 1955, 54:558-559.
Blom, K.F., et al., “Preparative LC-MS purification: improved compound-specific method optimization”,J. Comb. Chem., 2004, 6:874-883.
Aktories, K., et al., “Nicotinic acid inhibits adipocyte adenylate cyclase in a hormone-like mannter”FEBS Letters, 1980, 115:11-14.
Aktories, K., et al., “Islet-activating protein prevent nicotinic acid-induced GTPase stimulation and GTP but not GTP gamma S-induced adenylate cyclase inhibition in rat adipocytes”,FEBS Letters, 1983, 156:88-92.
Defronzo, R.A., “Dysfunctional fat cells, lipotoxicity and type 2 diabetes”,Int. J. Clin. Prac. 2004, 58:9-21.
Higuchi, T. et al., “Pro-drugs as Novel Delivery Systems”, vol. 14 of the A.C.S. Symposium Series, (1975).
Lorenzen, A., et al., “Characterization of a G Protein-Coupled Receptor for Nicotinic Acid”,Mol. Pharm, 2001, 59:349-357.
Nicolaou, K.C. et al., “Lipoxins and related eicosanoids: Biosynthesis, Biological Properties, and Chemical Synthesis”,Angnew. Chem., Int. Engl., 1991, 30:1100.
Sonogashira, K., et al., ., “A convenienet synthesis of acetylenes: catalytic substitutions of acetylenic hydrogen with bromoalkenes, iodoarenes and bromopyridines”,Tetrahedron Letters, 1975, p. 4467.
Taylor, A. et al., ., “Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated with Statins”,Circulation, 2004, 110:3512-3517.
Tunaru, S., et al., “PUMA-G and HM74 are receptors for nicotinic acid and mediate its antilipolytic effect”,Nat. Med., , 2003, 9:352-355.
Wise, et al., “Molecular Identification of High and Low Affinity Receptors for Nicotinic Acid”,J. Biol. Chem., 2003, 278:9869-9874.
Various contributors to Nature Medicine special focus on atherosclerosis ,Nature Med., 2002, 8:1209-1262.
Linton, M.F., et al.,NCEP ATP III, Am. J. Cardio., 2003, 92:19i-26i.
Garcia-Calvo, M. et al., The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1), ,PNAS, 2005, 102:8132-8137.
Remington's Pharmaceutical Sciences, 17thed., Mack Publishing Company, Easton, PA., p. 1418, (1985).
Journal of Pharmaceutical Science, 66, 2, 1977.
Bioreversible Carriers in Drug Design, Edward B. Roche, ed., American Pharmaceutical Associateion and Pergamon Press, 1987.
Green et al.,Protective Groups in Organic Synthesis, 2nded., Wiley and Sons, 1991.
Temple, D.L., et al., Substituted 6,7-dihydroimidazo[1,2-a]purin-9(4H)-ones,Journal of Medicinal Chemistry, 23(11), 1188-98, 1980.
Mueller, C., et al., “Imidazo[2,1,1]purin-5-ones and Related Tricyclic Water-Soluble Purine Derivatives: Potent AZA-and A3-Adenosine Receptor Antagonists”,Journal of Medicinal Chemistry, 45(16), 3440-3450, 2002.
Notice of Co-Pending Applications, 2009.
Office Action dated Oct. 19, 2010 received in copending U.S. Appl. No. 12/263,990.
Wolff, Manfred E., Burger's Medicinal Chemistry and Drug Discovery, Fifth Ed., vol. 1: Principles and Practice, John Wiley & Sons, 1995, p. 975-977.
Banker et al., Modern Pharmaceutics, Marcel Dekker, New York, 1996, p. 451, p. 596.
Notice of allowance dated Oct. 28, 2010 received in copending U.S. Appl. No. 12/237794.

Affiliated with

Also associated with

Rating

Purinone derivatives as HM74A agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Purinone derivatives as HM74A agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purinone derivatives as HM74A agonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2737676